Harrow is an eyecare-focused pharmaceutical company that commercializes branded and compounded ophthalmic medicines for eye-care professionals and patients in North America. Its portfolio covers essential eye therapies and a specialized compounding arm (including ImprimisRx) aimed at accessible, high-value treatments. The business concentrates exclusively on ophthalmology rather than broad-spectrum pharmaceuticals.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 47.8 | — | -17.8 | — |
| Q2 2025 | 63.7 | — | 5 | — |
| Q3 2025 | 71.6 | — | 1 | — |
| Q4 2025 | 89.1 | — | 6.6 | — |
| Q1 2026 | 44.2 | -7.6% | -27.6 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Community Trust Bancorp, Inc. (CTBI), FuelCell Energy, Inc. (FCEL), Capital Clean Energy Carriers Corp. (CCEC), Wealthfront Corporation (WLTH), G-III Apparel Group, Ltd. (GIII), Boxabl Inc. (BXBL)